Sponsored by Sanofi
Primary Objective: To evaluate the long-term safety and tolerability of UshStat® in patients with Usher syndrome type 1B Secondary Objective: To assess long-term safety and biological activity of UshStat®
Study Start Date: September 2013
Estimated Completion Date: October 2032
Specialties: Ophthalmology: Low Vision,Retina Otolaryngology: Otology/Neurotology
Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.
|A study to determine the long-term safety, tolerability and biological activity of UshStat® in Usher syndrome type 1B Sanofi|
|TGF-beta resistant cytotoxic T-lymphocytes in treatment of EBV-positive nasopharyngeal carcinoma / RESIST-NPC Baylor College of Medicine|
|Natural history of craniofacial anomalies and developmental growth variants National Institutes of Health Clinical Center (CC)|
Don't Have Account? Sign Up here.
Enter your email address and a password reset email will be sent to you.
Please submit one of the following:
— Action Required —
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.